Movatterモバイル変換


[0]ホーム

URL:


PhilPapersPhilPeoplePhilArchivePhilEventsPhilJobs
Order:

1 filter applied
  1.  36
    Do Clinicians Have a Duty to Participate in Pragmatic Clinical Trials?Andrew Garland,Stephanie Morain &Jeremy Sugarman -2022 -American Journal of Bioethics 23 (8):22-32.
    Clinicians have good moral and professional reasons to contribute to pragmatic clinical trials (PCTs). We argue that clinicians have a defeasible duty to participate in this research that takes place in usual care settings and does not involve substantive deviation from their ordinary care practices. However, a variety of countervailing reasons may excuse clinicians from this duty in particular cases. Yet because there is a moral default in favor of participating, clinicians who wish to opt out of this research must (...) justify their refusal. Reasons to refuse include that the trial is badly designed in some way, that the trial activities will violate the clinician’s conscience, or that the trial will impose excessive burdens on the clinician. (shrink)
    Direct download(3 more)  
     
    Export citation  
     
    Bookmark   18 citations  
  2.  126
    The limitations of "vulnerability" as a protection for human research participants.Carol Levine,Ruth Faden,Christine Grady,Dale Hammerschmidt,Lisa Eckenwiler &Jeremy Sugarman -2004 -American Journal of Bioethics 4 (3):44 – 49.
    Vulnerability is one of the least examined concepts in research ethics. Vulnerability was linked in the Belmont Report to questions of justice in the selection of subjects. Regulations and policy documents regarding the ethical conduct of research have focused on vulnerability in terms of limitations of the capacity to provide informed consent. Other interpretations of vulnerability have emphasized unequal power relationships between politically and economically disadvantaged groups and investigators or sponsors. So many groups are now considered to be vulnerable in (...) the context of research, particularly international research, that the concept has lost force. In addition, classifying groups as vulnerable not only stereotypes them, but also may not reliably protect many individuals from harm. Certain individuals require ongoing protections of the kind already established in law and regulation, but attention must also be focused on characteristics of the research protocol and environment that present ethical challenges. (shrink)
    Direct download(4 more)  
     
    Export citation  
     
    Bookmark   101 citations  
  3.  78
    Trust: The Fragile Foundation of Contemporary Biomedical Research.Nancy E. Kass,Jeremy Sugarman,Ruth Faden &Monica Schoch-Spana -1996 -Hastings Center Report 26 (5):25-29.
    It is widely assumed that informing prospective subjects about the risks and possible benefits of research not only protects their rights as autonomous decisionmakers, but also empowers them to protect their own interests. Yet interviews with patient‐subjects conducted under the auspices of the Advisory Committee on Human Radiation Experiments suggest this is not always the case. Patient‐subjects often trust their physician to guide them through decisions on research participation. Clinicians, investigators, and IRBs must assure that such trust is not misplaced.
    Direct download(2 more)  
     
    Export citation  
     
    Bookmark   42 citations  
  4.  45
    Moral Standards for Research in Developing Countries from "Reasonable Availability" to "Fair Benefits".Maged El Setouhy,Tsiri Agbenyega,Francis Anto,Christine Alexandra Clerk,Kwadwo A. Koram,Michael English,Rashid Juma,Catherine Molyneux,Norbert Peshu,Newton Kumwenda,Joseph Mfutso-Bengu,Malcolm Molyneux,Terrie Taylor,Doumbia Aissata Diarra,Saibou Maiga,Mamadou Sylla,Dione Youssouf,Catherine Olufunke Falade,Segun Gbadegesin,Reidar Lie,Ferdinand Mugusi,David Ngassapa,Julius Ecuru,Ambrose Talisuna,Ezekiel Emanuel,Christine Grady,Elizabeth Higgs,Christopher Plowe,Jeremy Sugarman &David Wendler -2004 -Hastings Center Report 34 (3):17.
  5.  40
    Examining Provisions Related to Consent in the Revised Common Rule.Jeremy Sugarman -2017 -American Journal of Bioethics 17 (7):22-26.
    The long-standing overarching policy governing research with human subjects conducted and supported by most federal agencies and departments in the United States, known as the Common Rule, has recently been revised, with most requirements slated to become effective in 2018. Although there are multiple alterations to the current regulations, some of the most significant changes aim to enhance consent for research. While some of the particular provisions in this regard will be easy to apply and promise to help meet this (...) goal, others may be more challenging to implement despite their intuitive appeal. In this article, I examine some of the provisions in the revised Common Rule that relate to consent: new required consent elements; the goal of comprehension in the consent process; consent forms; and broad consent. By raising issues about these provisions now and suggesting possible ways to overcome their potential shortfalls, the hope is that future efforts can be taken to help clarify and appropriately implement them. (shrink)
    Direct download(4 more)  
     
    Export citation  
     
    Bookmark   15 citations  
  6.  76
    Evaluating community engagement in global health research: the need for metrics.Kathleen M. MacQueen,Anant Bhan,Janet Frohlich,Jessica Holzer &Jeremy Sugarman -2015 -BMC Medical Ethics 16 (1):1-9.
    BackgroundCommunity engagement in research has gained momentum as an approach to improving research, to helping ensure that community concerns are taken into account, and to informing ethical decision-making when research is conducted in contexts of vulnerability. However, guidelines and scholarship regarding community engagement are arguably unsettled, making it difficult to implement and evaluate.DiscussionWe describe normative guidelines on community engagement that have been offered by national and international bodies in the context of HIV-related research, which set the stage for similar work (...) in other health related research. Next, we review the scholarly literature regarding community engagement, outlining the diverse ethical goals ascribed to it. We then discuss practical guidelines that have been issued regarding community engagement. There is a lack of consensus regarding the ethical goals and approaches for community engagement, and an associated lack of indicators and metrics for evaluating success in achieving stated goals. To address these gaps we outline a framework for developing indicators for evaluating the contribution of community engagement to ethical goals in health research.SummaryThere is a critical need to enhance efforts in evaluating community engagement to ensure that the work on the ground reflects the intentions expressed in the guidelines, and to investigate the contribution of specific community engagement practices for making research responsive to community needs and concerns. Evaluation mechanisms should be built into community engagement practices to guide best practices in community engagement and their replication across diverse health research settings. (shrink)
    Direct download(6 more)  
     
    Export citation  
     
    Bookmark   18 citations  
  7.  26
    Ethics and Collateral Findings in Pragmatic Clinical Trials.Stephanie R. Morain,Kevin Weinfurt,Juli Bollinger,Gail Geller,Debra J. H. Mathews &Jeremy Sugarman -2020 -American Journal of Bioethics 20 (1):6-18.
    Pragmatic clinical trials offer important benefits, such as generating evidence that is suited to inform real-world health care decisions and increasing research efficiency. However, PCTs also present ethical challenges. One such challenge involves the management of information that emerges in a PCT that is unrelated to the primary research question, yet may have implications for the individual patients, clinicians, or health care systems from whom or within which research data were collected. We term these findings as?pragmatic clinical trial collateral findings,? (...) or?PCT-CFs?. In this article, we explore the ethical considerations associated with the identification, assessment, and management of PCT-CFs, and how these considerations may vary based upon the attributes of a specific PCT. Our purpose is to map the terrain of PCT-CFs to serve as a foundation for future scholarship as well as policy-making and to facilitate careful deliberation about actual cases as they occur in practice. (shrink)
    Direct download(2 more)  
     
    Export citation  
     
    Bookmark   9 citations  
  8.  13
    Beyond Consent: Seeking Justice in Research.Jeffrey P. Kahn,Anna C. Mastroianni &Jeremy Sugarman (eds.) -1998 - Oup Usa.
    Beyond Consent examines the concept of justice, and its application to human subject research, through the different lenses of various research populations: children, the vulnerable sick, captive and convenient populations, women, people of colour, and subjects in international settings. Separate chapters address the evolution of research policies, implications of the concept of justice for the future of human subject research, and the ramifications of this concept throughout the research enterprise.
    No categories
    Direct download  
     
    Export citation  
     
    Bookmark   18 citations  
  9.  103
    Ethics in human subjects research: Do incentives matter?Ruth W. Grant &Jeremy Sugarman -2004 -Journal of Medicine and Philosophy 29 (6):717 – 738.
    There is considerable confusion regarding the ethical appropriateness of using incentives in research with human subjects. Previous work on determining whether incentives are unethical considers them as a form of undue influence or coercive offer. We understand the ethical issue of undue influence as an issue, not of coercion, but of corruption of judgment. By doing so we find that, for the most part, the use of incentives to recruit and retain research subjects is innocuous. But there are some instances (...) where it is not. Specifically, incentives become problematic when conjoined with the following factors, singly or in combination with one another: where the subject is in a dependency relationship with the researcher, where the risks are particularly high, where the research is degrading, where the participant will only consent if the incentive is relatively large because the participant's aversion to the study is strong, and where the aversion is a principled one. The factors we have identified and the kinds of judgments they require differ substantially from those considered crucial in most previous discussions of the ethics of employing incentives in research with human subjects. (shrink)
    Direct download(7 more)  
     
    Export citation  
     
    Bookmark   32 citations  
  10.  44
    Toward Meeting the Obligation of Respect for Persons in Pragmatic Clinical Trials.Stephanie R. Morain,Stephanie A. Kraft,Benjamin S. Wilfond,Amy Mcguire,Neal W. Dickert,Andrew Garland &Jeremy Sugarman -2022 -Hastings Center Report 52 (3):9-17.
    Hastings Center Report, Volume 52, Issue 3, Page 9-17, May–June 2022.
    Direct download(4 more)  
     
    Export citation  
     
    Bookmark   4 citations  
  11.  66
    Patients' Views on Identifiability of Samples and Informed Consent for Genetic Research.Sara Chandros Hull,Richard Sharp,Jeffrey Botkin,Mark Brown,Mark Hughes,Jeremy Sugarman,Debra Schwinn,Pamela Sankar,Dragana Bolcic-Jankovic,Brian Clarridge &Benjamin Wilfond -2008 -American Journal of Bioethics 8 (10):62-70.
    It is unclear whether the regulatory distinction between non-identifiable and identifiable information—information used to determine informed consent practices for the use of clinically derived samples for genetic research—is meaningful to patients. The objective of this study was to examine patients' attitudes and preferences regarding use of anonymous and identifiable clinical samples for genetic research. Telephone interviews were conducted with 1,193 patients recruited from general medicine, thoracic surgery, or medical oncology clinics at five United States academic medical centers. Wanting to know (...) about research being done was important to 72% of patients when samples would be anonymous and to 81% of patients when samples would be identifiable. Only 17% wanted to know about the identifiable scenario but not the anonymous scenario. Curiosity-based reasons were the most common among patients who wanted to know about anonymous samples. Of patients wanting to know about either scenario, approximately 57% would require researchers to seek permission, whereas 43% would be satisfied with notification only. Patients were more likely to support permission in the anonymous scenario if they had more education, were Black, less religious, in better health, more private, and less trusting of researchers. The sample, although not representative of the general population, does represent patients at academic medical centers whose clinical samples may be used for genetic research. Few patients expressed preferences consistent with the regulatory distinction between non-identifiable and identifiable information. Data from this study should cause policy-makers to question whether this distinction is useful in relation to research with previously collected clinically derived samples. (shrink)
    Direct download(2 more)  
     
    Export citation  
     
    Bookmark   20 citations  
  12.  85
    (1 other version)Addressing ethical challenges in HIV prevention research with people who inject drugs.Liza Dawson,Steffanie A. Strathdee,Alex John London,Kathryn E. Lancaster,Robert Klitzman,Irving Hoffman,Scott Rose &Jeremy Sugarman -2018 -Journal of Medical Ethics 44 (3):149-158.
    Despite recent advances in HIV prevention and treatment, high HIV incidence persists among people who inject drugs. Difficult legal and political environments and lack of services for PWID likely contribute to high HIV incidence. Some advocates question whether any HIV prevention research is ethically justified in settings where healthcare system fails to provide basic services to PWID and where implementation of research findings is fraught with political barriers. Ethical challenges in research with PWID include concern about whether research evidence will (...) be translated into practice; concerns that research might exacerbate background risks; and ethical challenges regarding the standard of HIV prevention in research. While these questions arise in other research settings, for research with PWID, these questions are especially controversial. This paper analyses four ethical questions in determining whether research could be ethically acceptable: Can researchers ensure that research does not add to the burden of social harms and poor health experienced by PWID? Should research be conducted in settings where it is uncertain whether research findings will be translated into practice? When best practices in prevention and care are not locally available, what standard of care and prevention is ethically appropriate? Does the conduct of research in settings with oppressive policies constitute complicity? We outline specific criteria to address these four ethical challenges. We also urge researchers to join the call to action for policy change to provide proven safe and effective HIV prevention and harm reduction interventions for PWID around the world. (shrink)
    Direct download(6 more)  
     
    Export citation  
     
    Bookmark   8 citations  
  13.  62
    Dealing With the Long-Term Social Implications of Research.Jeremy Sugarman,Dale E. Hammerschmidt,Christine Grady,Lisa Eckenwiler,Carol Levine &Alan Fleischman -2011 -American Journal of Bioethics 11 (5):5-9.
    Biomedical and behavioral research may affect strongly held social values and thereby create significant controversy over whether such research should be permitted in the first place. Institutional review boards responsible for protecting the rights and welfare of participants in research are sometimes faced with review of protocols that have significant implications for social policy and the potential for negative social consequences. Although IRB members often raise concerns about potential long-term social implications in protocol review, federal regulations strongly discourage IRBs from (...) considering them in their decisions. Yet IRBs often do consider the social implications of research protocols and sometimes create significant delays in initiating or even prevent such research. The social implications of research are important topics for public scrutiny and professional discussion. This article examines the reasons that the federal regulations preclude IRBs from assessing the social risks of research, and examines alternative approaches that have been used with varying success by national advisory groups to provide such guidance. The article concludes with recommendations for characteristics of a national advisory group that could successfully fulfill this need, including sustainability, independence, diverse and relevant expertise, and public transparency. (shrink)
    Direct download(2 more)  
     
    Export citation  
     
    Bookmark   15 citations  
  14.  57
    The Future of Empirical Research in Bioethics.Jeremy Sugarman -2004 -Journal of Law, Medicine and Ethics 32 (2):226-231.
    Empirical research in bioethics can be defined as the application of research methods in the social sciences to the direct examination of issues in [bioethics]. As such, empirical work is a form of descriptive ethics, focused on describing a particular state of affairs that has some moral or ethical relevance. For example, empirical research can help to describe cultural beliefs about the appropriateness of providing health-related information, such as the diagnosis of a life-threatening illness, which informs deliberations about the extent (...) to which it is morally important for clinicians to provide comprehensive information to patients in different cultural contexts. Similarly, empirical research can delineate popular attitudes and experiences related to contentious issues such as abortion, cloning, stem-cell research, and physician-assisted suicide to enlighten discussions and policy formulations regarding them. (shrink)
    Direct download(2 more)  
     
    Export citation  
     
    Bookmark   20 citations  
  15.  75
    Special Supplement: Empirical Research on Informed Consent: An Annotated Bibliography.Jeremy Sugarman,Douglas C. McCrory,Donald Powell,Alex Krasny,Betsy Adams,Eric Ball &Cynthia Cassell -1999 -Hastings Center Report 29 (1):S1.
  16.  54
    The Task Force Responds.Baruch Brody,Nancy Dubler,Jeff Blustein,Arthur Caplan,Jeffrey P. Kahn,Nancy Kass,Bernard Lo,Jonathan Moreno,Jeremy Sugarman &Laurie Zoloth -2002 -Hastings Center Report 32 (3):22-23.
  17.  36
    Reframing Recruitment: Evaluating Framing in Authorization for Research Contact Programs.Candace D. Speight,Charlie Gregor,Yi-An Ko,Stephanie A. Kraft,Andrea R. Mitchell,Nyiramugisha K. Niyibizi,Bradley G. Phillips,Kathryn M. Porter,Seema K. Shah,Jeremy Sugarman,Benjamin S. Wilfond &Neal W. Dickert -2021 -AJOB Empirical Bioethics 12 (3):206-213.
    No categories
    Direct download(2 more)  
     
    Export citation  
     
    Bookmark   3 citations  
  18.  70
    Medical and nursing students' television viewing habits: Potential implications for bioethics.Matthew J. Czarny,Ruth R. Faden,Marie T. Nolan,Edwin Bodensiek &Jeremy Sugarman -2008 -American Journal of Bioethics 8 (12):1 – 8.
    Television medical dramas frequently depict the practice of medicine and bioethical issues in a strikingly realistic but sometimes inaccurate fashion. Because these shows depict medicine so vividly and are so relevant to the career interests of medical and nursing students, they may affect these students' beliefs, attitudes, and perceptions regarding the practice of medicine and bioethical issues. We conducted a web-based survey of medical and nursing students to determine the medical drama viewing habits and impressions of bioethical issues depicted in (...) them. More than 80% of medical and nursing students watch television medical dramas. Students with more clinical experience tended to have impressions that were more negative than those of students without clinical experience. Furthermore, viewing of television medical dramas is a social event and many students discuss the bioethical issues they observe with friends and family. Television medical dramas may stimulate students to think about and discuss bioethical issues. (shrink)
    Direct download(4 more)  
     
    Export citation  
     
    Bookmark   12 citations  
  19.  41
    Categorizing Empirical Research in Bioethics: Why Count the Ways?Jeremy Sugarman,Nancy Kass &Ruth Faden -2009 -American Journal of Bioethics 9 (6-7):66-67.
  20.  56
    Allocation of Opportunities to Participate in Clinical Trials during the Covid‐19 Pandemic and Other Public Health Emergencies.Kayte Spector-Bagdady,Holly Fernandez Lynch,Barbara E. Bierer,Luke Gelinas,Sara Chandros Hull,David Magnus,Michelle N. Meyer,Richard R. Sharp,Jeremy Sugarman,Benjamin S. Wilfond,Ruqaiijah Yearby &Seema Mohapatra -2021 -Hastings Center Report 52 (1):51-58.
    Hastings Center Report, Volume 52, Issue 1, Page 51-58, January/February 2022.
    Direct download(2 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  21.  84
    Patients' views concerning research on medical practices: Implications for consent.Kevin P. Weinfurt,Juli M. Bollinger,Kathleen M. Brelsford,Travis J. Crayton,Rachel J. Topazian,Nancy E. Kass,Laura M. Beskow &Jeremy Sugarman -2016 -AJOB Empirical Bioethics 7 (2):76-91.
  22.  43
    What Patients Say about Medical Research.Jeremy Sugarman,Nancy E. Kass,Steven N. Goodman,Patricia Perentesis,Praveen Fernandes &Ruth R. Faden -1998 -IRB: Ethics & Human Research 20 (4):1.
  23.  60
    A Response to Commentators on “The Limitations of 'Vulnerability' as a Protection for Human Research Participants”.Carol Levine,Ruth Faden,Christine Grady,Dale Hammerschmidt,Lisa Eckenwiler &Jeremy Sugarman -2004 -American Journal of Bioethics 4 (3):W32-W32.
  24.  102
    Ethical Considerations in Determining Standard of Prevention Packages for HIV Prevention Trials: Examining PrEP.Bridget Haire,Morenike Oluwatoyin Folayan,Catherine Hankins,Jeremy Sugarman,Sheena McCormack,Gita Ramjee &Mitchell Warren -2013 -Developing World Bioethics 13 (2):87-94.
    The successful demonstration that antiretroviral (ARV) drugs can be used in diverse ways to reduce HIV acquisition or transmission risks – either taken as pre-exposure prophylaxis (PrEP) by those who are uninfected or as early treatment for prevention (T4P) by those living with HIV – expands the armamentarium of existing HIV prevention tools. These findings have implications for the design of future HIV prevention research trials. With the advent of multiple effective HIV prevention tools, discussions about the ethics and the (...) feasibility of future HIV prevention trial designs have intensified. This article outlines arguments concerning the inclusion of newly established ARV-based HIV prevention interventions as standard of prevention in HIV prevention trials from multiple perspectives. Ultimately, there is a clear need to incorporate stakeholders in a robust discussion to determine the appropriate trial design for each study population. (shrink)
    Direct download(5 more)  
     
    Export citation  
     
    Bookmark   5 citations  
  25.  52
    Response to Open Peer Commentaries on “Medical and Nursing Students' Television Viewing Habits: Potential Implications for Bioethics”.Matthew Czarny,Ruth Faden,Marie Nolan,Edwin Bodensiek &Jeremy Sugarman -2008 -American Journal of Bioethics 8 (12):1-1.
    Television medical dramas frequently depict the practice of medicine and bioethical issues in a strikingly realistic but sometimes inaccurate fashion. Because these shows depict medicine so vividly and are so relevant to the career interests of medical and nursing students, they may affect these students' beliefs, attitudes, and perceptions regarding the practice of medicine and bioethical issues. We conducted a web-based survey of medical and nursing students to determine the medical drama viewing habits and impressions of bioethical issues depicted in (...) them. More than 80% of medical and nursing students watch television medical dramas. Students with more clinical experience tended to have impressions that were more negative than those of students without clinical experience. Furthermore, viewing of television medical dramas is a social event and many students discuss the bioethical issues they observe with friends and family. Television medical dramas may stimulate students to think about and discuss bioethical issues. (shrink)
    Direct download(2 more)  
     
    Export citation  
     
    Bookmark   7 citations  
  26.  55
    Understanding Treatment with Respect and Dignity in the Intensive Care Unit.Hanan Aboumatar,Lindsay Forbes,Emily Branyon,Joseph Carrese,Gail Geller,Mary Catherine Beach &Jeremy Sugarman -2015 -Narrative Inquiry in Bioethics 5 (1):55-67.
    Despite wide recognition of the importance of treating patients with respect and dignity, little is known about what constitutes treatment in this regard. The intensive care unit (ICU) is a unique setting that can pose specific threats to treatment with respect and dignity owing to the critical state of patients, stress and anxiety amongst patients and their family members, and the highly technical nature of the environment. In attempt to understand various stakeholders’ perspectives of treatment with respect and dignity, patients (...) and family members were interviewed, a wide range of health care professionals participated in focus groups, and third party observers took field notes of interactions in the ICU. This paper compares and contrasts the data that were generated using these different methods. Triangulating the data in this way contributes to a more complete and nuanced understanding of treatment with respect and dignity in the ICU. (shrink)
    Direct download(5 more)  
     
    Export citation  
     
    Bookmark   4 citations  
  27.  59
    Developing ethics guidance for HIV prevention research: the HIV Prevention Trials Network approach.Stuart Rennie &Jeremy Sugarman -2010 -Journal of Medical Ethics 36 (12):810-815.
    More than 25 years into the HIV epidemic, in excess of 2 million new infections continue to occur each year. HIV prevention research is crucial for groups at heightened risk for HIV, but the design and conduct of HIV prevention research with vulnerable populations worldwide raises considerable ethical challenges. The HIV Prevention Trials Network (HPTN) is a global collaborative network that conducts clinical and behavioural studies on non-vaccine interventions to reduce the transmission of HIV. In 2003, the HPTN developed ethical (...) guidance to enhance the responsible conduct of its research activities and as a distinctive contribution to global research ethics. In what follows, the developments that motivated the drafting of a revised ethics document in 2009 are described, including the process by which that revision took place and some of the key differences between the HPTN ethics guidance and other relevant guidelines in the field. (shrink)
    Direct download(9 more)  
     
    Export citation  
     
    Bookmark   6 citations  
  28.  32
    Conducting Empirical Research on Informed Consent: Challenges and Questions.Greg A. Sachs,Gavin W. Hougham,Jeremy Sugarman,Patricia Agre,Marion E. Broome,Gail Geller,Nancy Kass,Eric Kodish,Jim Mintz,Laura W. Roberts,Pamela Sankar,Laura A. Siminoff,James Sorenson &Anita Weiss -2003 -IRB: Ethics & Human Research 25 (5):S4.
    No categories
    Direct download(2 more)  
     
    Export citation  
     
    Bookmark   7 citations  
  29.  37
    Toward Responsible Public Engagement in Neuroethics.J. Lomax Boyd &Jeremy Sugarman -2022 -American Journal of Bioethics Neuroscience 13 (2):103-106.
  30.  83
    Reflections on Governance Models for the Clinical Translation of Stem Cells.Jeremy Sugarman -2010 -Journal of Law, Medicine and Ethics 38 (2):251-256.
    Acentral promise of human embryonic stem cell research is the potential to develop viable therapeutic approaches to a range of devastating diseases and conditions. Despite excitement over such advances, there are scientific and medical reasons to be cautious as stem cells and their products are introduced into patients. In response to such concerns, the International Society for Stem Cell Research as well as ad hoc groups and individuals have offered approaches to governance of this research. While there are similarities among (...) these governance models and they are in principle easily endorsable, in this paper I raise a set of concerns related to their implementation, suggesting areas where gathering data may facilitate more appropriate oversight. Next, I suggest areas that seem to have been neglected as these governance models have been developed so that they may be on the agendas of those seeking to revise these models in the future. Finally, I describe how some of the concerns that have arisen in considering the appropriate governance of stem cell research may be useful in science and translational research more broadly. (shrink)
    Direct download(3 more)  
     
    Export citation  
     
    Bookmark   5 citations  
  31.  48
    An intervention to improve cancer patients' understanding of early-phase clinical trials.Nancy E. Kass,Jeremy Sugarman,Amy M. Medley,Linda A. Fogarty,Holly A. Taylor,Christopher K. Daugherty,Mark R. Emerson,Steven N. Goodman,Fay J. Hlubocky &Herbert I. Hurwitz -2009 -IRB: Ethics & Human Research 31 (3):1.
    Participants in clinical research sometimes view participation as therapy or exaggerate potential benefits, especially in phase I or phase II trials. We conducted this study to discover what methods might improve cancer patients’ understanding of early-phase clinical trials. We randomly assigned 130 cancer patients from three U.S. medical centers who were considering enrollment in a phase I or phase II cancer trial to receive either a multimedia intervention or a National Cancer Institute pamphlet explaining the trial and its purpose. Intervention (...) participants were 32 times more likely to believe that the trial’s purpose was to examine safety and 60 % less likely to believe they would experience long-term benefit or cure. There was no difference in enrollment decision. However, while patients’ understanding of the trial’s purpose improved and expectations of long-term benefit diminished, half the respondents still believed they would experience long-term benefit or cure from participation. Therefore, we conclude that multimedia interventions such as this one may help oncologists to explain the risks and benefits of early-phase cancer trials in a way that patients can more easily understand, helping them to make more informed decisions about participation. But further research into other factors that influence patients’ beliefs about the outcome of enrollment is needed, both to modify the interventions and to determine how malleable patient beliefs are. (shrink)
    Direct download  
     
    Export citation  
     
    Bookmark   5 citations  
  32.  54
    Toward Treatment With Respect and Dignity in the Intensive Care Unit.Jeremy Sugarman -2015 -Narrative Inquiry in Bioethics 5 (1):1-4.
    Despite concern that patients in the intensive care unit (ICU) may not be treated with respect and dignity, there is not conceptual clarity regarding what constitutes such treatment. In addition, measures specific to treatment with respect and dignity in the ICU are unavailable. Accordingly, a multidisciplinary group developed a conceptual model for treatment with respect and dignity in the ICU and used mixed methods to gather data on this issue. This effort included interviews with patients and families, focus groups with (...) health care professionals, and direct observations. These data were then compared and contrasted to synthesize what was learned. Finally, pilot quantitative patient and family survey data were collected and analyzed. Each of these approaches, which comprise the papers in this supplement to Narrative Inquiry in Bioethics, is briefly described in this article. (shrink)
    Direct download(6 more)  
     
    Export citation  
     
    Bookmark   3 citations  
  33.  52
    Patient and Family Perspectives on Respect and Dignity in the Intensive Care Unit.Mary Catherine Beach,Lindsay Forbes,Emily Branyon,Hanan Aboumatar,Joseph Carrese,Jeremy Sugarman &Gail Geller -2015 -Narrative Inquiry in Bioethics 5 (1):15-25.
    Respect and dignity are central to moral life, and have a particular importance in health care settings such as the intensive care unit (ICU). We conducted 15 semistructured interviews with 21 participants during an ICU admission to explore the definition of, and specific behaviors that demonstrate, respect and dignity during treatment in the ICU. We transcribed interviews and conducted thematic qualitative analysis. Seven themes emerged that focused on what it means to be treated with respect and/or dignity: treated as a (...) person; Golden Rule; acknowledgement; treated as family/friend; treated as an individual; treated as important/valuable; and treated as equal. Participants described particular behaviors or actions that were considered related to demonstrating treatment with respect and dignity: listening; honesty/giving information; attention to body/modesty/appearance; caring/bedside manner; patient and family as an information source; attention to pain; and responsiveness. These behaviors provide a framework for improving experiences with care in the ICU. (shrink)
    Direct download(4 more)  
     
    Export citation  
     
    Bookmark   3 citations  
  34.  45
    Health Care Professionals’ Perceptions and Experiences of Respect and Dignity in the Intensive Care Unit.Gail Geller,Emily Branyon,Lindsay Forbes,Cynda H. Rushton,Mary Catherine Beach,Joseph Carrese,Hanan Aboumatar &Jeremy Sugarman -2015 -Narrative Inquiry in Bioethics 5 (1):27-42.
    Little is known about health care professionals’ perceptions regarding what it means to treat patients and families with respect and dignity in the intensive care unit (ICU) setting. To address this gap, we conducted nine focus groups with different types of health care professionals (attending physicians, residents/fellows, nurses, social workers, pastoral care, etc.) working in either a medical or surgical ICU within the same academic health system. We identified three major thematic domains, namely, intrapersonal (attitudes and beliefs), interpersonal (behaviors), and (...) system (contextual) factors that influence treatment with respect and dignity. Participants suggested strategies for improving treatment of patients and families in the ICU with respect and dignity, as well as the related need for enhancing respect among the multidisciplinary team of clinicians. Implementing these strategies will require innovative educational interventions and leadership. Future research should focus on the design and evaluation of such interventions on the quality of care. (shrink)
    Direct download(4 more)  
     
    Export citation  
     
    Bookmark   3 citations  
  35.  51
    Implementing post-trial access plans for HIV prevention research.Amy Paul,Maria W. Merritt &Jeremy Sugarman -2018 -Journal of Medical Ethics 44 (5):354-358.
    Ethics guidance increasingly recognises that researchers and sponsors have obligations to consider provisions for post-trial access to interventions that are found to be beneficial in research. Yet, there is little information regarding whether and how such plans can actually be implemented. Understanding practical experiences of developing and implementing these plans is critical to both optimising their implementation and informing conceptual work related to PTA. This viewpoint is informed by experiences with developing and implementing PTA plans for six large-scale multicentre HIV (...) prevention trials supported by the HIV Prevention Trials Network. These experiences suggest that planning and implementing PTA often involve challenges of planning under uncertainty and confronting practical barriers to accessing healthcare systems. Even in relatively favourable circumstances where a tested intervention medication is approved and available in the local healthcare system, system-level barriers can threaten the viability of PTA plans. The aggregate experience across these HIV prevention trials suggests that simply referring participants to local healthcare systems for PTA will not necessarily result in continued access to beneficial interventions for trial participants. Serious commitments to PTA will require additional efforts to learn from future approaches, measuring the success of PTA plans with dedicated follow-up and further developing normative guidance to help research stakeholders navigate the complex practical challenges of realising PTA. (shrink)
    Direct download(5 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  36.  52
    Ethical Considerations in the Manufacture, Sale, and Distribution of Genome Editing Technologies.Jeremy Sugarman,Supriya Shivakumar,Martha Rook,Jeanne F. Loring,Christoph Rehmann-Sutter,Jochen Taupitz,Jutta Reinhard-Rupp &Steven Hildemann -2018 -American Journal of Bioethics 18 (8):3-6.
  37.  31
    Rethinking Human Embryo Research Policies.Kirstin R. W. Matthews,Ana S. Iltis,Nuria Gallego Marquez,Daniel S. Wagner,Jason Scott Robert,Inmaculada de Melo-Martín,Marieke Bigg,Sarah Franklin,Soren Holm,Ingrid Metzler,Matteo A. Molè,Jochen Taupitz,Giuseppe Testa &Jeremy Sugarman -2021 -Hastings Center Report 51 (1):47-51.
    It now seems technically feasible to culture human embryos beyond the “fourteen‐day limit,” which has the potential to increase scientific understanding of human development and perhaps improve infertility treatments. The fourteen‐day limit was adopted as a compromise but subsequently has been considered an ethical line. Does it remain relevant in light of technological advances permitting embryo maturation beyond it? Should it be changed and, if so, how and why? What justifications would be necessary to expand the limit, particularly given that (...) doing so would violate some people's moral commitments regarding human embryos? Robust stakeholder engagement preceded adoption of the fourteen‐day limit and should arguably be part of efforts to reassess it. Such engagement could also consider the need for enhanced oversight of human embryo research. In the meantime, developing and implementing reliable oversight systems should help foster high‐quality research and public confidence in it. (shrink)
    Direct download(2 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  38.  39
    Community consultation: Not the problem - an important part of the solution.Neal W. Dickert &Jeremy Sugarman -2006 -American Journal of Bioethics 6 (3):26 – 28.
  39.  58
    Empirical research on informed consent with the cognitively impaired.Gavin W. Hougham,Greg A. Sachs,Deborah Danner,Jim Mintz,Marian Patterson,Laura W. Roberts,Laura A. Siminoff,Jeremy Sugarman,Peter J. Whitehouse &Donna Wirshing -2003 -IRB: Ethics & Human Research 25 (5):s26 - 32.
  40.  98
    Informed Consent, Shared Decision-Making, and Complementary and Alternative Medicine.Jeremy Sugarman -2003 -Journal of Law, Medicine and Ethics 31 (2):247-250.
    Complementary and alternative medicine is used by many in hopes of achieving important health-related goals. Survey data indicate that 42 percent of the U.S. population uses CAM, accounting for 629 million “office” visits a year and expenditures of 27 billion dollars. This high prevalence of use calls for a careful evaluation of CAM so as to ensure the well-being of those using its modalities. Such an evaluation would obviously include assessments of the safety and efficacy of particular approaches, the training (...) and integrity of practitioners, and the appropriateness of modalities for different conditions or uses. Given the lack of published data concerning many of these aspects of CAM, the likely unfamiliarity of its practitioners to the approaches available to clinicians practicing modern scientific medcine, and the need to respect the unique preferences of persons seeking assistance with achieving health-related goals, it is also important to assess the potential roles of informed consent for the use of CAM. Examining such roles is the central task of this paper. (shrink)
    Direct download(2 more)  
     
    Export citation  
     
    Bookmark   5 citations  
  41.  33
    Questions concerning the Clinical Translation of Cell-Based Interventions under an Innovation Pathway.Jeremy Sugarman -2012 -Journal of Law, Medicine and Ethics 40 (4):945-950.
    Criticisms of the traditional clinical research pathway and its extensive oversight often focus on proposals for deregulation or assert that as in clinical treatment, clinical research should always offer benefit to patient-subjects. Proponents of medical innovation take a different, middle path, arguing that innovation is distinguishable from both research and treatment. This article considers this third pathway by examining stem cell-based innovation.Stem cell-based medical innovation is one pathway toward clinical translation. In fact, such an approach was taken in developing umbilical (...) cord blood transplantation, which is now widely viewed as a safe and effective means for treating a range of malignant and non-malignant conditions. While the Guidelines for the Clinical Translation of Stem Cells created by the International Society for Clinical Research provide an approach to clinical translation that involves “responsible innovation” as an alternative to clinical research, there are at least four sets of unanswered questions regarding the use of an innovation pathway in this context that warrant careful attention. (shrink)
    Direct download(2 more)  
     
    Export citation  
     
    Bookmark   3 citations  
  42.  48
    Are Research Subjects Adequately Protected? A Review and Discussion of Studies Conducted by the Advisory Committee on Human Radiation Experiments.Jeremy Sugarman &Nancy E. Kass -1996 -Kennedy Institute of Ethics Journal 6 (3):271-282.
    : In light of information uncovered about human radiation experiments conducted during the Cold War, an important charge for the Advisory Committee on Human Radiation Experiments was to assess the current state of protections for human research subjects. This assessment was designed to enhance the Committee's ability to make informed recommendations for the improvement of future policies and practices for the protection of research subjects. The Committee's examination of current protections revealed great improvement over those from the past, yet some (...) problems remain. Although the data collected by the Committee highlight specific areas in need of attention, the Committee's work should be viewed in part as the beginning of a series of ongoing assessments of the adequacy and effectiveness of the protections afforded to human subjects. (shrink)
    Direct download(4 more)  
     
    Export citation  
     
    Bookmark   4 citations  
  43.  54
    AJOB Empirical Bioethics: A Home for Empirical Bioethics Scholarship.Chris Feudtner,Jeremy Sugarman,Barbara A. Koenig,Peter A. Ubel,Richard F. Ittenbach,Laura Weiss Roberts &Laurence B. McCullough -2014 -AJOB Empirical Bioethics 5 (1):1-2.
  44.  79
    Policy recommendations for addressing privacy challenges associated with cell-based research and interventions.Ubaka Ogbogu,Sarah Burningham,Adam Ollenberger,Kathryn Calder,Li Du,Khaled El Emam,Robyn Hyde-Lay,Rosario Isasi,Yann Joly,Ian Kerr,Bradley Malin,Michael McDonald,Steven Penney,Gayle Piat,Denis-Claude Roy,Jeremy Sugarman,Suzanne Vercauteren,Griet Verhenneman,Lori West &Timothy Caulfield -2014 -BMC Medical Ethics 15 (1):7.
    The increased use of human biological material for cell-based research and clinical interventions poses risks to the privacy of patients and donors, including the possibility of re-identification of individuals from anonymized cell lines and associated genetic data. These risks will increase as technologies and databases used for re-identification become affordable and more sophisticated. Policies that require ongoing linkage of cell lines to donors’ clinical information for research and regulatory purposes, and existing practices that limit research participants’ ability to control what (...) is done with their genetic data, amplify the privacy concerns. (shrink)
    Direct download(8 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  45.  50
    Reviewing HIV‐Related Research in Emerging Economies: The Role of Government Reviewing Agencies.Patrina Sexton,Katrina Hui,Donna Hanrahan,Mark Barnes,Jeremy Sugarman,Alex John London &Robert Klitzman -2014 -Developing World Bioethics 16 (1):4-14.
    Little research has explored the possible effects of government institutions in emerging economies on ethical reviews of multinational research. We conducted semi-structured, in-depth telephone interviews with 15 researchers, Research Ethics Committees personnel, and a government agency member involved in multinational HIV Prevention Trials Network research in emerging economies. Ministries of Health or other government agencies often play pivotal roles as facilitators or barriers in the research ethics approval process. Government agency RECs reviewing protocols may face particular challenges, as they can (...) lack resources, be poorly organized, have inconsistent review processes and limited expertise, and use differing definitions of national interests, including upholding national reputation and avoiding potential exploitation and stigma of the country's population. The MOH/governmental review body may be affected by power dynamics and politics in study reviews; may consider issues both related and unrelated to research ethics as understood elsewhere; and may prioritize particular diseases, treatments, or interventions over other topics/types of research. Poor communication and deeply-rooted tensions may exist between sponsor and host countries, impeding optimal interactions and reviews. Investigators must understand and plan for the potential effects of governmental agencies on multinational collaborative research, including preserving adequate time for agency review, and contacting these agencies beforehand to address issues that may arise. Better understanding of these issues can aid and advance appropriate global scientific collaboration. (shrink)
    Direct download(3 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  46.  32
    Ethical Oversight of Multinational Collaborative Research: Lessons from Africa for Building Capacity and for Policy.Jeremy Sugarman &Participants in the Partnership for Enhancing Human Research Protections Durban Workshop1 -2007 -Research Ethics 3 (3):84-86.
    Researchers and others involved in the research enterprise from 12 African countries met with those working in ethics and oversight in the United States as part of an effort to develop research ethics capacity. Drawing on a wealth of experience among participants, discussions at the meeting revealed five categories of issues that warrant careful attention by those engaged in similar efforts as well as international policymakers and those charged with oversight of research. (1) Principal investigators should build ‘true research teams’ (...) where members of the team are meaningfully involved in decisions regarding the protocol and its implementation. (2)There should be explicit discussion about the ‘standard of care’ at the outset of project planning that includes clarification of the terminology that is being used. (3) While internationally collaborative research may involve populations that have inherent vulnerabilities, it is important to recognize the limitations of host country solutions (such as elaborated consent processes) and look for means to negotiate appropriate protections for those willing to participate. (4) In conducting research involving biological materials it would be prudent to develop material transfer agreements at the outset of the study to clarify expectations and to minimize the likelihood of harm. (5) Those engaged in internationally collaborative research need to be alert to the potential conflicts of interests of host country ethics committees during the approval process and to take measures to manage them if they indeed exist. (shrink)
    Direct download(2 more)  
     
    Export citation  
     
    Bookmark   3 citations  
  47.  63
    Using empirical data to inform the ethical evaluation of placebo controlled trials.Jeremy Sugarman -2004 -Science and Engineering Ethics 10 (1):29-35.
    There has been considerable debate about the ethical acceptability of using placebo-controls in clinical research. Although this debate has been rich in rhetoric, considering that much of this research is predicated upon the assumption that data from this research is vital to clinical decision-making, it is ironic that researchers have introduced little data into these discussions. Using some published research concerning the use of placebo-controls in clinical research in hypertension and psychiatric drug trials, I suggest some ways that such data (...) might be incorporated into the ethical analysis concerning placebo use in clinical trials. This approach promises to be important for enhancing conceptual and scientific understanding as well as public policy decision-making. (shrink)
    Direct download(3 more)  
     
    Export citation  
     
    Bookmark   3 citations  
  48.  60
    (1 other version)Bringing science and advocacy together to address health needs of people who inject drugs.Liza Dawson,Steffanie A. Strathdee,Alex John London,Kathryn E. Lancaster,Robert Klitzman,Irving Hoffman,Scott Rose &Jeremy Sugarman -2018 -Journal of Medical Ethics 44 (3):165-166.
    In crafting our paper on addressing the ethical challenges in HIV prevention research with people who inject drugs,1 we had hoped to stimulate further discussion and deliberation about the topic. We are pleased that three commentaries on our paper have begun this process.2 3 4 The commentaries rightly bring up important issues relating to community engagement and problems in translating research into practice in the fraught environments in which PWID face multiple risks. These risks include acquisition of HIV as well (...) as criminalisation, stigma and lack of access to needed healthcare, prevention and social services. We take this opportunity to respond to the excellent points raised by the commentators. All of the commentaries support our emphasis on robust community engagement with PWID and other stakeholders in designing and conducting HIV prevention research, but urge us to go farther. Wolfe highlights the difficulty of even engaging with community members in oppressive settings, where authorities severely restrict civil liberties of PWID so that even discussing issues related to drug use and enforcement may place individuals at risk. To overcome such limitations, he appropriately suggests interviewing confidentially those who have previously been detained in closed settings as part of the community engagement process. Similarly, Wolfe observes that critical issues can be overlooked with a narrow focus on study procedures if contextual factors before, during or after a study are ignored. For example, he cites the risk of overdose for study participants who have been abstinent during a study and subsequently resume injecting when the study concludes. These kinds of risks may not be obvious …. (shrink)
    Direct download(5 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  49.  58
    Using cognitive interviews to enhance measurement in empirical bioethics: Developing a measure of the preventive misconception in biomedical HIV prevention trials.Jeremy Sugarman,Damon M. Seils,J. Kemp Watson-Ormond &Kevin P. Weinfurt -2016 -AJOB Empirical Bioethics 7 (1):17-23.
  50.  78
    Disclosing Conflicts of Interest in Clinical Research: Views of Institutional Review Boards, Conflict of Interest Committees, and Investigators.Kevin P. Weinfurt,Joëlle Y. Friedman,Michaela A. Dinan,Jennifer S. Allsbrook,Mark A. Hall,Jatinder K. Dhillon &Jeremy Sugarman -2006 -Journal of Law, Medicine and Ethics 34 (3):581-591.
    Investigator and institutional financial conflicts of interest have raised concerns about both the integrity of clinical research and protecting the rights and welfare of research participants. In response, professional groups and governmental bodies have issued guidance for managing conflicts of interest to minimize their potential untoward effects. Although a variety of approaches have been offered, a common protection is to disclose financial interests in research to potential research participants as part of the recruitment and informed consent process. This approach reinforces (...) a basic norm of candor, ideally allowing potential research participants to evaluate whether financial interests should affect their decision to participate in research. Disclosure to potential research participants is viewed as an alternative to having regulators or research institutions limit or prohibit all financial interests in research, assuming that not all such interests are unacceptable. (shrink)
    Direct download(2 more)  
     
    Export citation  
     
    Bookmark   2 citations  
1 — 50 / 86
Export
Limit to items.
Filters





Configure languageshere.Sign in to use this feature.

Viewing options


Open Category Editor
Off-campus access
Using PhilPapers from home?

Create an account to enable off-campus access through your institution's proxy server or OpenAthens.


[8]ページ先頭

©2009-2025 Movatter.jp